[5] Fukushige S I, Matsubara K I, Yoshida M, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line[J]. Molecular and Cellular Biology, 1986, 6(3): 955-958. [6] Slamon D J, Clark G M, Wong...
41Gene expression changes responsible for lapatinib acquired resistance in HER2 positive gastric cancer cell lines: a microarray analysisBackground: Gastric cancer remains a major health problem worldwide. Treatment of advanced gastric cancer is controversial and there is no standard regimen for first- ...
[19] Updated analysis of DESTINY-Gastric02: A phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable/metastatic gastric/gastroesophageal junction (GEJ) cancer who...
[5] Kong Y, Dong Q, Jin P, et al.Updated Efficacy and Safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer. ESMO ASIA.2024.158P. [6] Janjigian, Y.Y., ...
五、DESTINY-Gastric 04研究——T-DXd二线单药头对头对比标准方案 2022年《CSCO胃癌诊疗指南》将雷莫西尤单抗联合紫杉醇方案作为HER2阳性晚期胃癌患者二线治疗的Ⅰ级1A类方案,正在进行的DESTINY-Gastric 04研究则将头对头对比此类患者中T-DXd单药与标准方案的疗效与安全性[22]。
[4]Chua C,Tan IB,Yamada Y,et al.Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.Cancer Chemother Pharmacol.2015 Aug;76(2):397-408. ...
2021年12月15日，纪念斯隆凯瑟琳癌症中心和康奈尔医学院的Yelena Y. Janjigian在Nature上发表题为The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer的文章，招募了434位HER2呈阳性，并患有胃肠道恶性肿瘤的病人，以随机双盲原则，进行PD-1抗体药物与曲妥珠单抗和化疗联合用药（...
[12]Uy NF,Merkhofer CM,Baik CS.HER2 in Non-Small Cell Lung Cancer:A Review of Emerging Therapies.Cancers 2022,14(17),4155 [13]NCCN guideline on gastric cancer v2022.2 [14]Peter C T-P et al.Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or ...
Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data Objectives: To compare the second-line treatments on survival after trastuzumab failure in HER2-positive metastatic gastric cancer. Methods: We retrospecti... A Topcu,M Besiroglu,MM Atci,.....
[15]Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol. 2019 Jun;20(6):827-836. [16]Shitara K, Bang YJ, Iwasa S, et al; Trastuzumab Deruxtecan in Previ...